ArticleBMC infectious diseases2025
Trends in the seroprevalence of hepatitis C viruses among patients received at the Centre Pasteur du Cameroun, with an indication of anti-HCV Ac serology from 2019 to 2024.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) remains one of the leading causes of morbidity and mortality worldwide, especially in resource-limited countries. Hepatitis C is a major cause of cirrhosis, liver cancer, and death. This study aimed to determine trends in the seroprevalence of hepatitis C among patients at the Centre Pasteur du Cameroun with anti-HCV antibody serology from 2019 to 2024.
methodsA retrospective study was conducted on patients who underwent HCV antibody testing. Plasma was analyzed for this marker using an Alinity i immunoassay kit (Abbott GmbH, Germany) during the period from 2019 to 2024. Data were entered and cleaned with Excel 2021. Binary logistic regression tests were performed using SPSS version 27. A p-value < 0.05 at a 95% confidence interval was considered statistically significant.
resultsA total of 31,429 participants were included in this study. The overall prevalence of anti-HCV was 13.50% (4245/31429). Anti-HCV seroprevalence was 13.48% (1857/13771) in men and 13.52% (2388/17658) in women. In this study, being over fifty-six years old (AOR 6.21; 95% CI 5.50–7.01; p < 0.001), being female (AOR 1.12; 95% CI 1.04–1.2; p = 0.002), and diagnosis in 2019 or 2020 with respective ranges (AOR 38; 95% CI 1.23–1.55; p < 0.001) and (AOR 1.15; 95% CI 1.03–1.3; p = 0.03) were significantly associated with hepatitis C seropositivity. Our study detected a high seroprevalence of hepatitis C virus antibodies, especially in women, those over fifty-six, and patients diagnosed in 2019 and 2020, who were most at risk.
conclusionSerious public health measures are urgently needed to reduce the disease burden and transmission, through systematic screening of all HCV infections by confirming risk cases with PCR, and health education campaigns for the population on the dangers associated with HCV infection. A national HCV control program, backed by a sustainable funding plan, is therefore needed to accelerate the elimination of HCV in Cameroon.
trial registrationThe study protocol was reviewed and approved by the Regional Ethics Committee for Human Health Research of the Center (CRERSH/C) (Number: E00571/ CRERSH/C /2023) and adhered to the ethical guidelines outlined in the 1975 Declaration of Helsinki.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.